SD
SDGR.US Schrodinger Inc
- Market cap
- USD 1.93B
- P/E
- -
- P/B
- 6.81x
- ROE
- -40.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SDGR.US undervalued?
Graham numberThe Graham number of Schrodinger Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Schrodinger Inc fundamental analysis
No fundamental analysis for Schrodinger Inc yet.
Schrodinger Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug D…
Full company profileSchrodinger Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Schrodinger Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 55.7M | 66.6M | 85.5M | 108M | 138M | 181M | 217M | 208M | 256M | 243M |
| Gross Profit | 39.8M | 42.9M | 49.1M | 63.5M | 65.6M | 101M | 141M | 132M | 143M | 134M |
| Operating Income | -19.0M | -28.0M | -38.7M | -60.9M | -111M | -147M | -177M | -209M | -167M | -155M |
| EBITDA | -17.3M | -25.1M | -35.1M | -57.3M | -98.0M | -145M | 48.5M | -180M | -96.3M | -114M |
| Net Income | -17.4M | -28.4M | -24.6M | -24.5M | -100M | -149M | 40.7M | -187M | -103M | -122M |
| EPS | -3.07 | -0.59 | -0.39 | -0.41 | -1.42 | -2.10 | 0.54 | -2.57 | -1.41 | -1.63 |
| Balance Sheet | ||||||||||
| Total Assets | 58.0M | 121M | 155M | 746M | 756M | 689M | 803M | 823M | 726M | 612M |
| Total Liabilities | 103M | 192M | 249M | 122M | 199M | 241M | 254M | 402M | 362M | 310M |
| Shareholders' Equity | -45.4M | -71.6M | -93.4M | 624M | 557M | 448M | 549M | 421M | 364M | 302M |
| Cash & Short-term Investments | 36.3M | 84.1M | 85.8M | 643M | 576M | 451M | 463M | 352M | 395M | 366M |
| Total Debt | - | - | 14.5M | 11.8M | 79.9M | 116M | 128M | 118M | 109M | 105M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -15.3M | -23.7M | -26.1M | 16.8M | -70.7M | -120M | -137M | -157M | 13.9M | 1.77M |
| Capital Expenditure | 3.70M | 5.26M | 1.84M | 2.54M | 7.17M | 8.01M | 13.4M | 7.31M | 1.44M | 5.54M |
| Free Cash Flow | -19.0M | -29.0M | -27.9M | 14.2M | -77.8M | -128M | -150M | -165M | 12.5M | -3.78M |
| Ratios | ||||||||||
| ROE | - | - | - | -3.9% | -18.0% | -33.3% | 7.4% | -44.4% | -28.4% | -40.5% |
| ROA | -30.0% | -23.5% | -15.8% | -3.3% | -13.3% | -21.7% | 5.1% | -22.7% | -14.2% | -20.0% |
| Net Profit Margin | -31.2% | -42.7% | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% | -50.4% |
| Debt to Equity | - | - | - | 0.02x | 0.14x | 0.26x | 0.23x | 0.28x | 0.30x | 0.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Schrodinger Inc dividends
Schrodinger Inc has not paid dividends in the last 9 fiscal years.
Who owns Schrodinger Inc
- Insiders 2.99%
- Institutions 94.51%
- Public & others 2.50%
- Shares outstanding 65.9M
- Free float 57.6M
Top funds holding SDGR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.43M | 4.57% | -0.18% | Oct 2026 |
| ARK Genomic Revolution ETF | 2.35M | 3.13% | +0.58% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.97M | 2.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.47M | 1.95% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.40M | 1.87% | -1.69% | Sep 2026 |
| Amova ARK Disruptive Innovation A USD | 1.39M | 1.86% | -3.62% | Sep 2026 |
| Amova ARK Pstv Chg Innovt P JPY Acc | 963K | 1.28% | -3.75% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 782K | 1.04% | -4.77% | Sep 2026 |
| Fidelity Small Cap Index | 634K | 0.84% | +0.23% | Aug 2026 |
| MFS New Discovery I | 600K | 0.80% | -33.84% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 543K | 0.72% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 521K | 0.69% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 516K | 0.69% | 0.00% | Oct 2026 |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 431K | 0.57% | -3.95% | Jul 2026 |
| ACATIS Datini Valueflex Fonds A | 387K | 0.52% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 336K | 0.45% | +0.95% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 324K | 0.43% | 0.00% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 312K | 0.42% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 303K | 0.40% | +0.23% | Oct 2026 |
| Nuveen Quant Small/Mid Cap Eq R6 | 280K | 0.37% | +30.72% | Sep 2026 |
Top institutions holding SDGR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.5M | 14.01% | +8.71% | Jun 2026 |
| Gates Bill & Melinda Foundation | 6.98M | 9.30% | 0.00% | Jun 2026 |
| Rubric Capital Management LP | 6.40M | 8.52% | +6.67% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.79M | 5.04% | -1.94% | Jun 2026 |
| Amova Asset Management Americas, Inc | 2.71M | 3.60% | -15.19% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 2.71M | 3.60% | -15.19% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.69M | 3.58% | +3.33% | Jun 2026 |
| State Street Corp | 2.30M | 3.06% | +4.88% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 2.22M | 2.96% | -16.49% | Jun 2026 |
| ARK Investment Management LLC | 2.15M | 2.87% | +4.20% | Jun 2026 |
| AQR Capital Management LLC | 1.96M | 2.61% | +340.46% | Jun 2026 |
| Geode Capital Management, LLC | 1.47M | 1.96% | +8.86% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.25M | 1.66% | -9.20% | Jun 2026 |
| UBS Group AG | 964K | 1.28% | -26.96% | Jun 2026 |
| Citadel Advisors Llc | 896K | 1.19% | +354.14% | Jun 2026 |
| Massachusetts Financial Services Company | 867K | 1.15% | -67.71% | Jun 2026 |
| The Goldman Sachs Group Inc | 733K | 0.98% | -2.62% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 732K | 0.98% | +15.10% | Sep 2026 |
| Northern Trust Corp | 650K | 0.87% | +13.33% | Jun 2026 |
| Nuveen, LLC | 614K | 0.82% | +388.17% | Jun 2026 |
Schrodinger Inc company profile
- Company name
- Schrodinger Inc
- Ticker
- SDGR.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2020
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 850
- Fiscal year end
- December
- Address
- 1540 Broadway, New York, NY, United States, 10036
- Phone
- 212 295 5800
- Website
- schrodinger.com
About Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrodinger Inc management
10- Dr. Ramy Farid Ph.D.CEO, President & Director · born 1965
- Dr. Karen Akinsanya Ph.D.President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships · born 1968
- Dr. Richard A. Friesner Ph.D.Co-Founder, Scientific Advisory Chairman and Director · born 1953
- Mr. Richie JainExecutive VP, CFO & Treasurer · born 1985
- Ms. Yvonne Tran Esq.Corporate Secretary, Chief Legal & People Officer · born 1971
- Prof. William Goddard III, Ph.D.Co-Founder & Scientific Advisor
- Mr. Kenneth Patrick LortonExecutive VP, CTO & COO of Software · born 1984
- Ms. Therese AbramsPrincipal Accounting Officer · born 1984
- Mr. Shane BraunerExecutive VP & Chief Information Officer · born 1977
- Ms. Jaren Irene MaddenChief Corporate Affairs Officer & Head of Investor Relations